Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia.

Authors :: Furman, Richard R.
Sharman, Jeff P.
Coutre, Steven E.
Cheson, Bruce D.
Pagel, John M.
Hillmen, Peter
Barrientos, Jacqueline C.
Zelenetz, Andrew D.
Kipps, Thomas J.
Flinn, Ian
Ghia, Paolo
Eradat, Herbert
Ervin, Thomas
Lamanna, Nicole
Coiffier, Bertrand
Pettitt, Andrew R.
Path, F. R. C.
Shuo Ma
Stilgenbauer, Stephan
Cramer, Paula
Source :: New England Journal of Medicine. 3/13/2014, Vol. 370 Issue 11, p997-1007. 11p.
Publication Year :: 2014
Abstract: The article discusses a phase 3 study which assessed the efficacy and safety of idelalisib, an oral inhibitor of the delta isoform of phosphatidylinositol 3-kinase, in combination with rituximab versus rituximab plus placebo in patients with relapsed chronic lymphocytic leukemia (CLL). It cites improvement in progression-free survival, overall response rate, and overall survival in patients receiving idelalisib and rituximab. It also mentions the occurrence of adverse events in some patients.